Oncology

BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies
Why BioNTech Is Trading Higher Today Following A Stock Upgrade From SVB Securities Analyst
Cannabotech To Manufacture Oncology Products Via Partnership With California Medical Cannabis Producer

Oncology Recent News

Crinetics Spins Off Radiopharmaceuticals Efforts Into New Company
Calithera Buys Two Oncology Candidates From Takeda For $45M
Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK).
Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings
Why Are TransCode Therapeutics Shares Shooting Higher On Thursday?
AbCellera, Everest Medicines Team Up To Develop 10 Therapeutic Antibodies
Oric Pharma To Launch Human Trial For CD73 Inhibitor Program In Q4
Why Are Silverback Therapeutics Shares Falling On Monday?
UK's NHS Launches World's Largest Trial Of Blood Test For 50 Types
Adaptimmune Shares Encouraging Data From Solid Tumor Trial
Three Analysts Initiate Coverage On This Newly Listed Precision Oncology Firm
Illumina, Merck Join Hands For Homologous Recombination Deficiency CDx, Research Assay
Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma
See Why RenovoRx Stock Is Shooting Higher On Tuesday
Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications
Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates
ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty
Rafael Starts Mid-Stage Biliary Tract Cancer Trial With CPI-613 Combo Regime
Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
What's Happening With Sonnet BioTherapeutics Stock?
Trading of Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock was halted thrice during the early morning session. No company-specific reports are driving up the stock price today, so it appears there are external factors at play.
Adagene Inks Third Cancer Trial Collaboration With Merck
Exelixis, Invenra Expand Oncology Pact
Merck's Belzutifan Wins FDA Approval As First Drug For Rare VHL Tumors
Mustang Bio, Mayo Clinic Join Forces On New CAR T Tech In Tumor Settings

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved